HQL vs. CET, QQQX, GAM, MUC, MFIC, SLRC, MQY, HQH, MYI, and PHK
Should you be buying Abrdn Life Sciences Investors stock or one of its competitors? The main competitors of Abrdn Life Sciences Investors include Central Securities (CET), Nuveen Nasdaq 100 Dynamic Overwrite Fund (QQQX), General American Investors (GAM), BlackRock MuniHoldings California Quality Fund (MUC), MidCap Financial Investment (MFIC), SLR Investment (SLRC), BlackRock MuniYield Quality Fund (MQY), Abrdn Healthcare Investors (HQH), BlackRock MuniYield Quality Fund III (MYI), and PIMCO High Income Fund (PHK). These companies are all part of the "investment offices, not elsewhere classified" industry.
Abrdn Life Sciences Investors (NYSE:HQL) and Central Securities (NYSE:CET) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.
Abrdn Life Sciences Investors received 95 more outperform votes than Central Securities when rated by MarketBeat users.
In the previous week, Abrdn Life Sciences Investors had 3 more articles in the media than Central Securities. MarketBeat recorded 5 mentions for Abrdn Life Sciences Investors and 2 mentions for Central Securities. Abrdn Life Sciences Investors' average media sentiment score of 1.06 beat Central Securities' score of 0.22 indicating that Abrdn Life Sciences Investors is being referred to more favorably in the media.
Abrdn Life Sciences Investors pays an annual dividend of $1.49 per share and has a dividend yield of 11.2%. Central Securities pays an annual dividend of $1.85 per share and has a dividend yield of 4.3%.
32.2% of Abrdn Life Sciences Investors shares are owned by institutional investors. Comparatively, 8.7% of Central Securities shares are owned by institutional investors. 10.1% of Abrdn Life Sciences Investors shares are owned by company insiders. Comparatively, 10.3% of Central Securities shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Abrdn Life Sciences Investors has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Central Securities has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.
Summary
Abrdn Life Sciences Investors beats Central Securities on 5 of the 7 factors compared between the two stocks.
Get Abrdn Life Sciences Investors News Delivered to You Automatically
Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HQL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Abrdn Life Sciences Investors Competitors List
Related Companies and Tools